- €925.19m
- €698.54m
- €857.18m
Annual cashflow statement for Neurones SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 42.9 | 51.8 | 58.6 | 63.2 | 61.9 |
| Depreciation | |||||
| Non-Cash Items | 21 | 23.9 | 20.7 | 19.9 | 18.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -14.1 | -37.3 | -24 | -16.4 | -28.5 |
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 64.5 | 55 | 72.1 | 84.4 | 71.3 |
| Capital Expenditures | -6.58 | -10.6 | -18 | -12 | -10.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -4.04 | -1.65 | -3.59 | -7.65 | -10.7 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -10.6 | -12.3 | -21.6 | -19.7 | -21.2 |
| Financing Cash Flow Items | -0.486 | -4.67 | 3.12 | 2.01 | 7.56 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -55.4 | -36.1 | -27.1 | -34.5 | -35.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.42 | 6.89 | 23.5 | 30.6 | 14.2 |